Immix Biopharma (IMMX) Total Non-Current Liabilities (2020 - 2024)
Quarterly results put Total Non-Current Liabilities at $9.7 million for Q4 2024, up 160.54% from a year ago — trailing twelve months through Dec 2024 was $9.7 million (up 160.54% YoY), and the annual figure for FY2024 was $9.7 million, up 160.54%.
Immix Biopharma has reported Total Non-Current Liabilities over the past 5 years, most recently at $9.7 million for Q4 2024.
- Total Non-Current Liabilities reached $9.7 million in Q4 2024 per IMMX's latest filing, up from $7.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $9.7 million in Q4 2024 and bottomed at -$23.2 million in Q4 2021.
- Median Total Non-Current Liabilities over the past 5 years was $4.8 million (2020), compared with a mean of $2.0 million.
- The largest annual shift saw Total Non-Current Liabilities tumbled 594.4% in 2021 before it surged 160.54% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $4.7 million in 2020, then crashed by 594.4% to -$23.2 million in 2021, then soared by 107.53% to $1.7 million in 2022, then skyrocketed by 112.88% to $3.7 million in 2023, then soared by 160.54% to $9.7 million in 2024.
- Business Quant data shows Total Non-Current Liabilities for IMMX at $9.7 million in Q4 2024, $7.6 million in Q3 2024, and $4.9 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 7.32 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 9.70 Mn |
| Sep 30, 2024 | 7.59 Mn |
| Jun 30, 2024 | 4.94 Mn |
| Mar 31, 2024 | 6.72 Mn |
| Dec 31, 2023 | 3.72 Mn |
| Dec 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | -23.21 Mn |
| Dec 31, 2020 | 4.70 Mn |